T-DXd plus a RAGE inhibitor for advanced HER2-positive or HER2-low breast cancer
Treatments studied
This study tests a new combination treatment for metastatic breast cancer that is HER2-positive or HER2-low and has stopped responding to T-DXd. The combination includes T-DXd plus a new drug that targets RAGE. The goal is to see if this combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have breast cancer that has spread to other parts of the body (metastatic).
- Your cancer must be HER2-positive or HER2-low, as determined by a biopsy.
- Your cancer must have progressed while on T-DXd (trastuzumab deruxtecan) therapy.
- You must have measurable disease, meaning tumors that can be seen on scans.
- You must have adequate organ function, including kidneys, liver, and blood counts.
- You must be able to swallow capsules.
- You must not be pregnant or breastfeeding, and if of childbearing age, you must agree to use contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is studying a drug called T-DXd (trastuzumab deruxtecan) for Chinese women with advanced breast cancer that has a certain protein (HER2) either in high or low amounts. It aims to see how well the drug works in real-world settings.
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
This trial compares a targeted antibody-drug conjugate called T-DXd against standard hormone therapy for women with HR+, HER2-low advanced breast cancer that has progressed after first-line endocrine therapy plus a CDK4/6 inhibitor. It aims to see if T-DXd works better than continuing hormone therapy alone.
This trial tests a drug called T-DXd (a targeted chemotherapy) combined with hormone therapy for people with HER2-positive and hormone receptor-positive advanced breast cancer who have not had prior treatment for their metastatic disease. It includes an upfront phase, a maintenance phase, and a retreatment phase to see if restarting T-DXd is effective.
This trial compares two treatments for advanced breast cancer that is HR-positive, HER2-low or ultralow, and a non-luminal subtype. It tests if a targeted antibody-drug conjugate (T-DXd) works better than the usual first-line therapy combining a CDK4/6 inhibitor with hormone therapy. This study is for people who have not had any treatment for advanced disease.
This trial tests a combination of two drugs, T-DXd (a targeted therapy) and an immunotherapy, before surgery for people with early-stage breast cancer that has low levels of HER2 and is hormone receptor positive. The goal is to see if this treatment can shrink the tumor or eliminate cancer cells before surgery.
Hear when a new T-dxd Resistant HER2-Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.